Fresenius Medical Care is trading at $21.67, down 4.16%, after cutting its 2026 profit outlook. - November 3, 2026, third-quarter results: management expects full-year operating income to range from flat to a mid-single-digit decline, versus prior guidance allowing mid-single-digit growth. - U.S. same-market treatments fell 1.1% in the quarter, while reported operating income also reflected €108 million in China strategy costs. - Revenue beat estimates, but the outlook cut and volume weakness were the clearest company-specific catalysts.